MATERIALS AND METHODS
Study Population and Sampling. Data presented in this paper were derived from several studies that are part of two separate ongoing projects aimed to determine the population frequency of clinically relevant genetic variants in the Republic of Macedonia and establish their association with the risk for occurrence of various cancer diseases (colorectal, prostate, breast), with the disease prognosis and therapy outcome.
Taking this into account, the study group used for the genotyping of SULT1A1, UGT1A1, GSTT1, MTHFR and TYMS-TSER genetic variants, consisted of 96 adults (40 males and 56 females; average age 74.52 ± 10.46) without any history of a malignant disease and 94 newborns (29 males and 65 females) who were used as normal controls in the previously mentioned studies. Since both control groups showed a similar genotype distribution, the results have been integrated in these further calculations. In addition, 184 individuals (162 males and 22 females, aged 32.23 ± 9.38years), volunteers for the clinical studies of bioequivalence and bioavailability, were recruited for the genotyping of drug metabolizing enzyme (DME) genetic variants (CYP2D6, CYP2C19, CYP2C9 and CYP3A5). All subjects were unrelated healthy donors of European origin who were selfdeclared ethnic Macedonians.
Ethical approval was obtained from the Research Ethics Committee of the Faculty of Pharmacy and the Ethics Committee of the Ministry of Health of the Republic of Macedonia. Both study projects were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants in the study before the collection of the specimens. All personal identifiers were removed; isolated DNA samples were tested anonymously. Missing genotype data for some of the subjects in both study groups was due to the lack of a DNA sample.
Genotyping Procedures. Genomic DNA was extracted from peripheral blood samples using Proteinase K digestion/phenol-chloroform extraction and ethanol precipitation. 
